Update shared on15 Aug 2025
Fair value Increased 10%Analysts raised their price target for SANUWAVE Health from $49.00 to $54.00 following strong Q2 results, upward revisions to FY25 AEBITDA and continued revenue guidance confidence, reflecting increased conviction in profitability and growth.
Analyst Commentary
- Bullish analysts cited strong Q2 results as a key driver for the price target increase.
- The company reiterated its FY25 revenue forecast of $48M-$50M, signaling continued confidence in growth.
- Analysts raised FY25 AEBITDA estimates to $15.2M from $14.2M, reflecting improved profitability projections.
- The consistent Buy rating was maintained due to positive operating momentum and execution.
- Upward price target adjustment reflects increased conviction in the firm's earnings trajectory.
What's in the News
- SANUWAVE Health provided Q3 2025 revenue guidance of $12 million to $12.7 million and reiterated full-year 2025 revenue guidance of $48 million to $50 million, representing a 47% to 53% increase versus 2024.
- The company was added to several Russell indices, including Russell 2000, 2500, 3000, Microcap, Small Cap Completeness, and multiple associated growth and dynamic indices.
- SANUWAVE Health was also added to the S&P TMI Index.
Valuation Changes
Summary of Valuation Changes for SANUWAVE Health
- The Consensus Analyst Price Target has significantly risen from $49.00 to $54.00.
- The Net Profit Margin for SANUWAVE Health has significantly risen from 21.44% to 25.93%.
- The Future P/E for SANUWAVE Health has significantly fallen from 31.97x to 27.09x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.